EE200200471A - Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks - Google Patents

Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks

Info

Publication number
EE200200471A
EE200200471A EEP200200471A EEP200200471A EE200200471A EE 200200471 A EE200200471 A EE 200200471A EE P200200471 A EEP200200471 A EE P200200471A EE P200200471 A EEP200200471 A EE P200200471A EE 200200471 A EE200200471 A EE 200200471A
Authority
EE
Estonia
Prior art keywords
derivative
camptothecin
cancer
treatment
combination
Prior art date
Application number
EEP200200471A
Other languages
English (en)
Estonian (et)
Inventor
Bissery Marie-Christine
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200200471A publication Critical patent/EE200200471A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200471A 2000-02-28 2001-02-26 Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks EE200200471A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US20893800P 2000-06-05 2000-06-05
PCT/EP2001/002723 WO2001062235A2 (fr) 2000-02-28 2001-02-26 Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer

Publications (1)

Publication Number Publication Date
EE200200471A true EE200200471A (et) 2003-12-15

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200471A EE200200471A (et) 2000-02-28 2001-02-26 Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks

Country Status (28)

Country Link
US (3) US6503889B2 (fr)
EP (1) EP1278518B1 (fr)
JP (1) JP2003523980A (fr)
KR (1) KR100717916B1 (fr)
CN (1) CN1424912A (fr)
AT (1) ATE344670T1 (fr)
AU (1) AU785467B2 (fr)
BR (1) BR0108728A (fr)
CA (1) CA2401191C (fr)
CY (1) CY1105803T1 (fr)
CZ (1) CZ298259B6 (fr)
DE (1) DE60124387T2 (fr)
DK (1) DK1278518T3 (fr)
EA (1) EA005619B1 (fr)
EE (1) EE200200471A (fr)
ES (1) ES2273841T3 (fr)
HR (1) HRP20020658A2 (fr)
HU (1) HUP0300848A3 (fr)
IL (1) IL150953A0 (fr)
MX (1) MXPA02008355A (fr)
NO (1) NO324772B1 (fr)
NZ (1) NZ520593A (fr)
PL (1) PL363110A1 (fr)
PT (1) PT1278518E (fr)
SK (1) SK12242002A3 (fr)
TW (1) TWI239841B (fr)
WO (1) WO2001062235A2 (fr)
YU (1) YU64602A (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU2003277424A1 (en) * 2002-10-17 2004-05-04 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
CN1964979B (zh) 2004-04-09 2011-07-27 中外制药株式会社 新颖的水溶性前药
EP1771174A1 (fr) * 2004-05-28 2007-04-11 Pfizer Products Inc. Technique de traitement de croissance cellulaire anormale
AU2005251769B2 (en) * 2004-06-04 2008-10-02 Novartis Ag Cancer treatment method
WO2005117980A1 (fr) * 2004-06-04 2005-12-15 Pfizer Products Inc. Methode de traitement de croissances cellulaires anormales
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
CA2604192A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Compositions a liberation modifiee contenant un derive de fluorocytidine pour le traitement du cancer
CN103735560A (zh) * 2005-06-07 2014-04-23 耶鲁大学 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP2427179A4 (fr) 2009-05-04 2013-09-11 Psivida Inc Particules de silicium poreux d'élution de médicament
SI3117709T1 (sl) * 2010-03-12 2018-12-31 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
EP2635255B1 (fr) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Dispositifs à base de silicium pouvant être biologiquement érodés pour administration d'agents thérapeutiques
JP2016512839A (ja) 2013-03-15 2016-05-09 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療物質の送達のための生体内分解性ケイ素系組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5951289A (ja) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (fr) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Derives de la campothecine et methode de preparation
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
EP0540099B1 (fr) 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Dérivés de camptothécine solubles dans l'eau
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
PT835258E (pt) 1995-06-21 2003-02-28 Sod Conseils Rech Applic Novos analogos de camptotecina, processos para a sua preparacao, sua utilizacao como farmacos e composicoes farmaceuticas que os contem
WO2000038519A1 (fr) * 1998-12-31 2000-07-06 Sugen, Inc. Composes 3-heteroarylidenyl-2-indolinone utilises pour modulation de l'activite de la proteine kinase et dans la chimiotherapie du cancer
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
AU6011101A (en) 2001-09-03
PT1278518E (pt) 2007-01-31
KR100717916B1 (ko) 2007-05-11
CA2401191C (fr) 2006-05-02
CA2401191A1 (fr) 2001-08-30
PL363110A1 (en) 2004-11-15
ES2273841T3 (es) 2007-05-16
NZ520593A (en) 2004-10-29
SK12242002A3 (sk) 2003-02-04
AU785467B2 (en) 2007-07-26
DE60124387D1 (de) 2006-12-21
US6503889B2 (en) 2003-01-07
BR0108728A (pt) 2003-12-30
DK1278518T3 (da) 2007-01-15
CZ298259B6 (cs) 2007-08-08
ATE344670T1 (de) 2006-11-15
US20020091132A1 (en) 2002-07-11
EA005619B1 (ru) 2005-04-28
IL150953A0 (en) 2003-02-12
YU64602A (sh) 2005-06-10
US20030096789A1 (en) 2003-05-22
WO2001062235A2 (fr) 2001-08-30
HUP0300848A2 (hu) 2003-08-28
EA200200922A1 (ru) 2003-04-24
JP2003523980A (ja) 2003-08-12
US20020068743A1 (en) 2002-06-06
NO20024076L (no) 2002-08-27
NO20024076D0 (no) 2002-08-27
DE60124387T2 (de) 2007-10-11
KR20020082856A (ko) 2002-10-31
NO324772B1 (no) 2007-12-10
MXPA02008355A (es) 2002-12-13
TWI239841B (en) 2005-09-21
HUP0300848A3 (en) 2005-03-29
US6664242B2 (en) 2003-12-16
CN1424912A (zh) 2003-06-18
EP1278518B1 (fr) 2006-11-08
CZ20022892A3 (cs) 2002-11-13
HRP20020658A2 (en) 2004-12-31
WO2001062235A3 (fr) 2002-11-14
CY1105803T1 (el) 2011-02-02
EP1278518A2 (fr) 2003-01-29

Similar Documents

Publication Publication Date Title
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
ATE531263T1 (de) Hemmer der bruton-tyrosinkinase
WO2001066123A3 (fr) Composition d'herbe medicinale phy906 et son utilisation en chimiotherapie
TR200100054T2 (tr) Paroksetin metansülfonat
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
EE200300184A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini kombinatsioonis stilbeeni derivaadiga, ning selle kasutamine vähktõve raviks
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DK1161254T3 (da) Behandling af autoimmune sygdomme med en ekstrakt af amerikansk ginseng
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
FR2812549B1 (fr) Associations dalfopristine/quinupristine avec le cefpirome
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof